Sensei Biotherapeutics, Inc. (SNSE)

1,7900 +0,1400 (+8,48%) Al cierre: 04:00PM EDT

Sensei Biotherapeutics, Inc.

1405 Research Boulevard
Suite 125
Rockville, MD 20850
United States
240 243 8000
https://www.senseibio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 28

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. John K. Celebi M.B.A.	President, CEO & Director	799,69k	N/A	1972
Ms. Lora Pike	Vice President of Investor Relations & Communications	N/A	N/A	N/A
Mr. Christopher W. Gerry J.D.	Senior VP, General Counsel & Secretary	N/A	N/A	N/A
Dr. Aaron Weitzman FACP, M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Gobierno corporativo

El ISS Governance QualityScore de Sensei Biotherapeutics, Inc., a día 1 de mayo de 2024, es 9. Las puntuaciones base son Auditoría: 9; Tablero: 7; Derechos de los accionistas: 10; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.